Skip to main content
. 2013 Mar 11;31(13):1662–1668. doi: 10.1200/JCO.2012.45.9453

Fig 3.

Fig 3.

(A) Cumulative incidence of disease progression or relapse according to random assignment groups. (B) Cumulative incidence of transplantation-related mortality according to random assignment groups. B-BEAM, iodine-131 tositumomab plus carmustine, etoposide, cytarabine, and melphalan; R-BEAM, rituximab plus carmustine, etoposide, cytarabine, and melphalan.